ESMO 2019 | Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma

Enrique Grande, MD, from the MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the results of his late-breaking abstract at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. The Phase 3 IMvigor130 trial (NCT02807636) evaluated the efficacy and safety of atezolizumab alone or in combination with platinum-based chemotherapy (PBC) vs. a placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma.